PL392964A1 - Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania - Google Patents

Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania

Info

Publication number: PL392964A1
Authority: PL; Poland
Prior art keywords: antigen; formulation; hyperimmune serum; serum reactive; hiperimmune
Prior art date: 2001-01-26

Application number

PL392964A

Other languages

English (en)

Other versions

PL214482B1 (pl

Inventor

Andreas Meinke

Ahsen Uwe Von

Christop Klade

Tamas Henics

Duc Bui Minh

Oresta Vytvytska

Hildegard Etz

Agnieszka Dryla

Thomas Weichhart

Martin Hafner

Brigitte Tempelmaier

Claire M. Fraser

Steven Gill

Wolfgang Zauner

Eszter Nagy

Original Assignee

Intercell Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-26

Filing date

2002-01-21

Publication date

2011-01-03

2002-01-21 Application filed by Intercell Ag filed Critical Intercell Ag

2011-01-03 Publication of PL392964A1 publication Critical patent/PL392964A1/pl

2013-08-30 Publication of PL214482B1 publication Critical patent/PL214482B1/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Computational Biology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL392964A 2001-01-26 2002-01-21 Antygen reaktywny wobec surowicy hiperimmunologicznej, zastosowanie tego antygenu, preparat farmaceutyczny zawierajacy antygen, szczepionka, przeciwcialo, preparat zawierajacy przeciwcialo, sposób wytwarzania preparatu i czasteczka kwasu nukleinowego PL214482B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT0013001A AT410798B (de)	2001-01-26	2001-01-26	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen

Publications (2)

Publication Number	Publication Date
PL392964A1 true PL392964A1 (pl)	2011-01-03
PL214482B1 PL214482B1 (pl)	2013-08-30

Family

ID=3636418

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL367125A PL209115B1 (pl)	2001-01-26	2002-01-21	Sposób identyfikowania, izolowania i wytwarzania antygenów od specyficznego patogenu
PL392964A PL214482B1 (pl)	2001-01-26	2002-01-21	Antygen reaktywny wobec surowicy hiperimmunologicznej, zastosowanie tego antygenu, preparat farmaceutyczny zawierajacy antygen, szczepionka, przeciwcialo, preparat zawierajacy przeciwcialo, sposób wytwarzania preparatu i czasteczka kwasu nukleinowego

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL367125A PL209115B1 (pl)	2001-01-26	2002-01-21	Sposób identyfikowania, izolowania i wytwarzania antygenów od specyficznego patogenu

Country Status (24)

Country	Link
US (4)	US7968297B2 (pl)
EP (6)	EP1630172B1 (pl)
JP (2)	JP2004531476A (pl)
KR (4)	KR20080107477A (pl)
CN (2)	CN1649894A (pl)
AT (2)	AT410798B (pl)
AU (3)	AU2002247641B8 (pl)
BR (1)	BR0207067A (pl)
CA (2)	CA2436057C (pl)
CZ (1)	CZ20032201A3 (pl)
DE (1)	DE60207194T2 (pl)
DK (1)	DK1355930T3 (pl)
ES (1)	ES2252438T3 (pl)
HU (1)	HUP0402048A3 (pl)
IL (4)	IL157082A0 (pl)
IS (1)	IS6895A (pl)
MX (1)	MXPA03006702A (pl)
NO (1)	NO20033364L (pl)
NZ (4)	NZ540764A (pl)
PL (2)	PL209115B1 (pl)
RU (1)	RU2289817C2 (pl)
SK (1)	SK10492003A3 (pl)
WO (1)	WO2002059148A2 (pl)
ZA (1)	ZA200305764B (pl)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1353689E (pt)	2001-01-03	2006-08-31	Epitopix Llc	Composicoes imunizantes e metodos de utilizacao
AT410798B (de)	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
US6841154B2 (en)	2001-06-15	2005-01-11	Inhibitex, Inc.	Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
GB0200865D0 (en) *	2002-01-16	2002-03-06	Univ Bristol	Method
GB2387600A (en) *	2002-04-19	2003-10-22	Pantherix Ltd	Pantothenate kinase
JP2006510353A (ja) *	2002-10-03	2006-03-30	インターツェル・アクチェンゲゼルシャフト	ハプトグロビン受容体リガンド結合と相互作用する分子の使用
CA2517518A1 (en)	2003-03-04	2004-09-16	Intercell Ag	Streptococcus pyogenes antigens
US7628994B2 (en)	2003-03-31	2009-12-08	Intercell Ag	S. epidermidis antigens
CN1774447B (zh)	2003-04-15	2011-04-06	英特塞尔股份公司	肺炎链球菌抗原
JP2007524366A (ja) *	2003-04-22	2007-08-30	インターツェル・アクチェンゲゼルシャフト	ピロリ菌抗原
EP1620460A2 (en)	2003-05-07	2006-02-01	Intercell AG	Streptococcus agalactiae antigens i + ii
CA2525540A1 (en)	2003-05-30	2004-12-09	Intercell Ag	Enterococcus antigens
CN1980692A (zh) *	2003-07-24	2007-06-13	麦克公司	用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
DK1651166T3 (da) *	2003-07-24	2010-05-31	Merck Sharp & Dohme	Polypeptid til induktion af et beskyttende immunrespons mod staphylococcus aureus
ES2395022T3 (es)	2003-09-19	2013-02-07	Epitopix, Llc	Polipéptidos de Campylobacter y sus métodos de uso
AU2005214061B2 (en) *	2004-02-18	2010-02-04	Merck Sharp & Dohme Corp.	Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20070172498A1 (en) *	2004-02-27	2007-07-26	Anderson Annaliesa S	Polypeptides for inducing a protective immune response against staphyloococcus aureus
JP2005278537A (ja) *	2004-03-30	2005-10-13	Dai Ichi Seiyaku Co Ltd	新規ポリペプチド
WO2005103073A2 (en) *	2004-04-27	2005-11-03	Intercell Ag	Td antigens
WO2006065272A2 (en)	2004-05-21	2006-06-22	Idaho Research Foundation, Inc.	Methods for altering acetic acid production and enhancing cell death in bacteria
JP2008500043A (ja) *	2004-05-25	2008-01-10	メルク　エンド　カムパニー　インコーポレーテッド	黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド
US20090317412A1 (en) *	2004-06-04	2009-12-24	Alexander Jeffery L	Induction of an immune response against streptococcus pneumoniae polyaccharides
FR2871237B1 (fr) *	2004-06-08	2011-03-11	Abag	Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
FR2871159A1 (fr) *	2004-06-08	2005-12-09	Abag Sa	Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
EP1784212A4 (en) *	2004-07-06	2008-09-17	Merck & Co Inc	POLYPEPTIDES FOR THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
US20080095792A1 (en) *	2004-09-17	2008-04-24	Anderson Annaliesa S	Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
CA2580103C (en)	2004-09-22	2021-11-16	Glaxosmithkline Biologicals S.A.	Immunogenic composition
CN101175508A (zh)	2004-10-21	2008-05-07	惠氏公司	表皮葡萄球菌多肽抗原的免疫原性组合物
AU2005298742B2 (en) *	2004-10-29	2010-08-12	Intercell Ag	HCV vaccines for chronic HCV patients
WO2006079076A2 (en)	2005-01-21	2006-07-27	Epitopix, Llc	Yersinia spp. polypeptides and methods of use
ES2589927T3 (es)	2005-01-21	2016-11-17	Merck Sharp & Dohme Corp.	Polipéptidos para inducir una respuesta inmunitaria protectora contra Staphylococcus aureus
ES2586125T3 (es)	2005-02-14	2016-10-11	Epitopix, Llc	Polipéptidos de Staphylococcus aureus y métodos de uso
JP2008534970A (ja) *	2005-04-04	2008-08-28	ヴィヴェンティアバイオテックインコーポレーティッド	抗原の同定のための方法および系
WO2006121664A2 (en) *	2005-05-05	2006-11-16	Merck & Co., Inc.	Polypeptides for inducing a protective immune response against staphylococcus aureus
US20070003954A1 (en) *	2005-05-12	2007-01-04	The Board Of Regents Of The University Of Texas System	Protein and antibody profiling using small molecule microarrays
BRPI0613026A2 (pt) *	2005-07-14	2012-01-03	Bharat Biotech Int Ltd	composiÇço, fragmento de nucleotÍdeo, constructo de dna recombinante, mÉtodo para produzir proteÍna, composiÇço farmacÊutica e mÉtodo para uso da mesma, formulaÇço, mÉtodo de administrar composiÇço farmacÊutica, mÉtodo de prevenÇço e controle de infecÇÕes associadas a staphylococcus
US20090317421A1 (en) *	2006-01-18	2009-12-24	Dominique Missiakas	Compositions and methods related to staphylococcal bacterium proteins
JP2009531387A (ja)	2006-03-30	2009-09-03	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
GB0610776D0 (en) *	2006-05-31	2006-07-12	Univ Bath	Novel applications for staphylococcus aureus Sbi protein
JP2010503384A (ja) *	2006-09-15	2010-02-04	インターセルアーゲー	ボレリア（Ｂｏｒｒｅｌｉａ）抗原
US20080102067A1 (en) *	2006-10-25	2008-05-01	Cook Mark E	Immunogenic composition
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP1935984A1 (en) *	2006-12-20	2008-06-25	Unilever N.V.	Screening method for the identification of a preservative
CA2675992A1 (en)	2007-01-24	2008-11-20	Merck & Co., Inc.	Polypeptides for inducing a protective immune response against staphylococcus epidermidis
WO2008115415A2 (en) *	2007-03-19	2008-09-25	Merck & Co., Inc	Polypeptides for inducing a protective immune response against staphylococcus epidermidis
CA2690271A1 (en) *	2007-06-18	2008-12-24	Intercell Ag	Chlamydia antigens
US9181329B2 (en)	2007-08-31	2015-11-10	The University Of Chicago	Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR101661946B1 (ko)	2007-08-31	2016-10-05	유니버시티 오브 시카고	스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
TW200930814A (en) *	2007-10-18	2009-07-16	Unilever Nv	Method for producing a foaming agent
CN101458255B (zh) *	2007-12-14	2013-03-06	武汉大学	丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法
US20090196852A1 (en) *	2008-02-04	2009-08-06	Watkinson D Tobin	Compositions and methods for diagnosing and treating immune disorders
SI2268618T1 (sl)	2008-03-03	2015-09-30	Novartis Ag	Spojine in sestavki kot modulatorji aktivnosti TLR
BRPI0909664A2 (pt)	2008-03-17	2019-09-24	Intercell Ag	peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos
WO2009158682A2 (en) *	2008-06-27	2009-12-30	Watkinson D Tobin	Compositions and methods for diagnosing and treating pathogenic disorders
US20100015171A1 (en) *	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
US8758765B2 (en)	2008-07-29	2014-06-24	The University Of Chicago	Compositions and methods related to Staphylococcal bacterium proteins
CA2738793A1 (en) *	2008-09-30	2010-04-08	University Of Maryland, Baltimore	Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2341929B1 (en) *	2008-10-06	2017-01-25	University Of Chicago	Compositions and methods related to bacterial emp proteins
MX2011004080A (es) *	2008-10-16	2011-07-28	Unilever Nv	Solucion de hidrofobina conteniendo antiespumante.
EP2376111A4 (en)	2008-11-26	2013-01-09	Merck Sharp & Dohme	POLYPEPTIDES FOR INDUCING PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
WO2010062814A1 (en)	2008-11-26	2010-06-03	Merck Sharp & Dohme Corp.	Polypeptides for inducing a protective immune response against staphylococcus aureus
SG195555A1 (en) *	2008-12-24	2013-12-30	Emd Millipore Corp	Caustic stable chromatography ligands
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
CN105582524A (zh) *	2009-03-23	2016-05-18	埃皮托皮克斯有限责任公司	多肽和含有革兰氏阳性多肽的免疫组合物及使用方法
EP3281947B1 (en)	2009-04-03	2020-02-12	The University of Chicago	Compositions and methods related to protein a (spa) variants
WO2011127032A1 (en)	2010-04-05	2011-10-13	University Of Chicago	Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
EP3263128A3 (en) *	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Compositions for immunising against staphylococcus aureus
CA2704702C (en) *	2009-06-02	2018-06-12	Unilever Plc	Aerated baked products
AU2010258677B2 (en)	2009-06-10	2016-10-06	Glaxosmithkline Biologicals S.A.	Benzonaphthyridine-containing vaccines
EP3238742A1 (en)	2009-06-22	2017-11-01	Wyeth LLC	Immunogenic compositions of staphylococcus aureus antigens
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
JO3257B1 (ar)	2009-09-02	2018-09-16	Novartis Ag	مركبات وتركيبات كمعدلات لفاعلية tlr
JP5988492B2 (ja)	2009-09-02	2016-09-07	ノバルティスアーゲー	Ｔｌｒ活性モジュレーターを含む免疫原性組成物
WO2011057148A1 (en)	2009-11-05	2011-05-12	Irm Llc	Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh)	2009-12-15	2012-10-31	诺华有限公司	免疫增强化合物的均匀悬液及其用途
US8765148B2 (en)	2010-02-19	2014-07-01	Valneva Austria Gmbh	1C31 nanoparticles
KR101853513B1 (ko)	2010-03-23	2018-04-30	노파르티스 아게	감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
BR112012029521A2 (pt)	2010-05-05	2018-03-06	New York University	leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas.
US8821894B2 (en)	2010-07-02	2014-09-02	The University Of Chicago	Compositions and methods related to protein A (SpA) variants
US9192661B2 (en)	2010-07-06	2015-11-24	Novartis Ag	Delivery of self-replicating RNA using biodegradable polymer particles
WO2012021229A1 (en)	2010-07-13	2012-02-16	Merck Sharp & Dohme Corp.	Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon
US9095540B2 (en)	2010-09-09	2015-08-04	The University Of Chicago	Methods and compositions involving protective staphylococcal antigens
WO2012065034A1 (en)	2010-11-12	2012-05-18	Merck Sharp & Dohme Corp.	Enolase peptide conjugate vaccines against staphylococcus aureus
CN102558316B (zh) *	2010-12-30	2015-07-01	上海雅心生物技术有限公司	高稳定性的具抗体结合能力的重组蛋白a及其生产
US8945588B2 (en) *	2011-05-06	2015-02-03	The University Of Chicago	Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2839554C (en)	2011-06-19	2023-09-26	New York University	Methods of treating and preventing staphylococcus aureus infections and associated conditions
CA2839558A1 (en)	2011-06-19	2012-12-27	New York University	Leukotoxin e/d as a new anti-inflammatory agent and microbicide
WO2013066731A2 (en)	2011-10-31	2013-05-10	Merck Sharp & Dohme Corp.	Protective vaccine based on staphylococcus aureus sa2451 protein
BR112014020427B1 (pt)	2012-02-20	2023-04-04	Swedish Orphan Biovitrum Ab (Publ)	Polipeptídeo de ligação de c5, composto de ligação de c5 e combinação
CA2910319C (en)	2012-04-26	2022-06-14	University Of Chicago	Staphylococcal coagulase antigens and methods of their use
US9376487B2 (en)	2012-07-10	2016-06-28	Merck Sharp & Dohme Corp.	Protective vaccine based on Staphylococcus aureus SA2493 protein
RU2526497C2 (ru) *	2012-10-31	2014-08-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации	Способ определения генотипов золотистого стафилококка
HUE049012T2 (hu) *	2012-11-06	2020-09-28	Medimmune Llc	Antitestek S. aureus felszíni determinánsok ellen
WO2014096333A1 (en) *	2012-12-20	2014-06-26	Morphosys Ag	Anti-staphylococcal antibodies
CN103965336B (zh) *	2013-01-29	2016-08-10	苏州偲聚生物材料有限公司	多肽、包含该多肽的检测器件和检测试剂盒
CN105188747A (zh)	2013-02-01	2015-12-23	葛兰素史密斯克莱生物公司	包含toll样受体激动剂的免疫组合物的皮内递送
RU2639527C2 (ru) *	2013-04-25	2017-12-21	ЭбТЛАС КО., Лтд.	Способ очистки белка, включенного в саморасщепляющуюся кассету, и его применение
LT3039033T (lt)	2013-08-28	2019-10-25	Affibody Ab	Surišantys polipeptidai, turintys mutuotą karkasą
LT3038633T (lt) *	2013-08-28	2021-03-25	Ipc Research, Llc	Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
CN104558196A (zh) *	2013-10-15	2015-04-29	温州医科大学	基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2542396C1 (ru) *	2013-11-06	2015-02-20	Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека	Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции
WO2015082536A1 (en) *	2013-12-03	2015-06-11	Evaxion Biotech Aps	Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
CN103694323B (zh) *	2013-12-09	2017-01-18	成都欧林生物科技股份有限公司	金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
US10100093B2 (en)	2013-12-31	2018-10-16	Epitopix Llc	Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
US20170165347A1 (en)	2014-06-30	2017-06-15	Murdoch Childrens Research Institute	Helicobacter therapeutic
CN104569386B (zh) *	2014-12-10	2016-05-11	中国水产科学研究院淡水渔业研究中心	一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法
JP6605606B2 (ja)	2014-12-17	2019-11-13	エフ．ホフマン−ラロシュアーゲー	ソルターゼを使用した単一工程での二重ポリペプチドコンジュゲーションのための酵素ワンポット反応
US10781246B2 (en)	2015-06-05	2020-09-22	New York University	Compositions and methods for anti-staphylococcal biologic agents
WO2017050874A1 (en)	2015-09-25	2017-03-30	F. Hoffmann-La Roche Ag	Process for producing thioesters employing a sortase a
JP6998863B2 (ja)	2015-09-25	2022-02-04	エフ．ホフマン－ラロシュアーゲー	深共融溶媒におけるソルターゼａを利用したアミド基転移
CN108138158B (zh)	2015-09-25	2021-11-09	豪夫迈·罗氏有限公司	可溶性分选酶a
ES2824479T3 (es)	2015-11-27	2021-05-12	Univ Masarykova	Polipéptido FGF2 termoestable, utilización del mismo
US10166280B2 (en)	2016-06-08	2019-01-01	Epitopix, Llc	Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en)	2016-10-18	2020-08-11	The Research Foundation for the State University	Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10504742B2 (en) *	2017-05-31	2019-12-10	Asm Ip Holding B.V.	Method of atomic layer etching using hydrogen plasma
WO2018237010A2 (en)	2017-06-20	2018-12-27	The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
AU2019218978A1 (en)	2018-02-12	2020-09-03	Inimmune Corporation	Toll-like receptor ligands
US10905738B2 (en) *	2018-07-05	2021-02-02	Biozeus Desenvolvimento De Produtos Biofarmacêuticos	Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2689161C1 (ru) *	2018-10-04	2019-05-24	Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека	Способ получения бактериальных антигенов
CN111110838A (zh) *	2019-12-24	2020-05-08	华南师范大学	一种罗非鱼无乳链球菌疫苗及其制备方法
CN111808977B (zh) *	2020-07-23	2023-06-27	清华大学深圳国际研究生院	一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法
CA3198876A1 (en)	2020-11-04	2022-05-12	Eligo Bioscience	Cutibacterium acnes recombinant phages, method of production and uses thereof
KR102306010B1 (ko) *	2021-04-07	2021-09-27	씨제이제일제당 (주)	신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법
KR102281369B1 (ko) *	2021-04-07	2021-07-22	씨제이제일제당 (주)	신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0462210B1 (en) *	1989-03-09	1994-09-07	Praxis Biologics, Inc.	Vaccines for nontypable haemophilus influenzae
US5980908A (en) *	1991-12-05	1999-11-09	Alfa Laval Ab	Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5456907A (en)	1992-01-10	1995-10-10	Helene Curtis, Inc.	Cysteamine permanent wave composition and method
US5700928A (en) *	1995-10-16	1997-12-23	Smithkline Beecham, P.L.C.	Polynucleotide encoding saliva binding protein
US6737248B2 (en) *	1996-01-05	2004-05-18	Human Genome Sciences, Inc.	Staphylococcus aureus polynucleotides and sequences
RS50101B (sr)	1996-02-24	2009-01-22	Boehringer Ingelheim International Gmbh.,	Farmaceutski preparati za imunomodulaciju
US6380370B1 (en) *	1997-08-14	2002-04-30	Genome Therapeutics Corporation	Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP1036321A1 (en) *	1997-12-05	2000-09-20	Intercell Biomedizinische Forschungs- und Entwicklungs GmbH	Method and cells to screen combinatorial libraries
DE19803453A1 (de)	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
AU771716B2 (en) *	1998-04-30	2004-04-01	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	New method for the selection of clones of an expression library involving rearraying
WO1999067376A1 (en) *	1998-06-25	1999-12-29	Institut Pasteur	Exhaustive analysis of viral protein interactions by two-hybrid screens and selection of correctly folded viral interacting polypeptides
US6610836B1 (en) *	1999-01-29	2003-08-26	Genome Therapeutics Corporation	Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
AT407643B (de) *	1999-02-01	2001-05-25	Intercell Biomedizinische Forschungs & Entwicklungs Gmbh	Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
US6936258B1 (en) *	1999-03-19	2005-08-30	Nabi Biopharmaceuticals	Staphylococcus antigen and vaccine
DK2230303T3 (da) *	1999-05-05	2013-04-15	Phylogica Ltd	Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker
DK1238102T3 (da) *	1999-08-06	2009-02-09	Oragenics Inc	Mikrobiel polynukleotider udtrykt under infektion af en vært
AT408721B (de)	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
US20020061569A1 (en)	2000-03-21	2002-05-23	Robert Haselbeck	Identification of essential genes in prokaryotes
AU2001281812B2 (en)	2000-06-08	2005-04-07	Valneva Austria Gmbh	Immunostimulatory oligodeoxynucleotides
GB0014907D0 (en) *	2000-06-20	2000-08-09	Univ Sheffield	Antigenic polypeptides
AU2001289813B2 (en)	2000-08-17	2005-07-28	Intercell Ag	A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
AT410798B (de)	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en)	2001-03-21	2002-10-08	Elitra Pharmaceuticals, Inc.	Identification of essential genes in microorganisms
GB0107661D0 (en) *	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
US6841154B2 (en)	2001-06-15	2005-01-11	Inhibitex, Inc.	Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
ATE542829T1 (de)	2001-08-02	2012-02-15	Univ Sheffield	Impfstoff
DK1651166T3 (da)	2003-07-24	2010-05-31	Merck Sharp & Dohme	Polypeptid til induktion af et beskyttende immunrespons mod staphylococcus aureus
ATE410798T1 (de)	2005-06-13	2008-10-15	Research In Motion Ltd	Elektrischer verbinder und elektrisches system für ein bauteil in einem elektronischen gerät

2001
- 2001-01-26 AT AT0013001A patent/AT410798B/de not_active IP Right Cessation
2002
- 2002-01-21 CN CNA028057651A patent/CN1649894A/zh active Pending
- 2002-01-21 EP EP05024214.8A patent/EP1630172B1/en not_active Expired - Lifetime
- 2002-01-21 CA CA2436057A patent/CA2436057C/en not_active Expired - Fee Related
- 2002-01-21 CZ CZ20032201A patent/CZ20032201A3/cs unknown
- 2002-01-21 BR BR0207067-7A patent/BR0207067A/pt not_active IP Right Cessation
- 2002-01-21 PL PL367125A patent/PL209115B1/pl unknown
- 2002-01-21 IL IL15708202A patent/IL157082A0/xx unknown
- 2002-01-21 ES ES02716669T patent/ES2252438T3/es not_active Expired - Lifetime
- 2002-01-21 EP EP10178468A patent/EP2412722A1/en not_active Withdrawn
- 2002-01-21 AU AU2002247641A patent/AU2002247641B8/en not_active Ceased
- 2002-01-21 KR KR1020087026439A patent/KR20080107477A/ko not_active Application Discontinuation
- 2002-01-21 HU HU0402048A patent/HUP0402048A3/hu unknown
- 2002-01-21 CN CNA2008101610502A patent/CN101492496A/zh active Pending
- 2002-01-21 JP JP2002559450A patent/JP2004531476A/ja active Pending
- 2002-01-21 EP EP05108422A patent/EP1616876A3/en not_active Withdrawn
- 2002-01-21 EP EP02716669A patent/EP1355930B1/en not_active Expired - Lifetime
- 2002-01-21 DK DK02716669T patent/DK1355930T3/da active
- 2002-01-21 NZ NZ540764A patent/NZ540764A/en not_active IP Right Cessation
- 2002-01-21 RU RU2003125967/13A patent/RU2289817C2/ru not_active IP Right Cessation
- 2002-01-21 MX MXPA03006702A patent/MXPA03006702A/es active IP Right Grant
- 2002-01-21 DE DE60207194T patent/DE60207194T2/de not_active Expired - Lifetime
- 2002-01-21 PL PL392964A patent/PL214482B1/pl unknown
- 2002-01-21 KR KR1020097017433A patent/KR20090101973A/ko not_active Application Discontinuation
- 2002-01-21 KR KR1020037009882A patent/KR100851728B1/ko not_active IP Right Cessation
- 2002-01-21 US US10/470,048 patent/US7968297B2/en not_active Expired - Fee Related
- 2002-01-21 KR KR1020087006114A patent/KR100901915B1/ko not_active IP Right Cessation
- 2002-01-21 NZ NZ565349A patent/NZ565349A/en not_active IP Right Cessation
- 2002-01-21 AT AT02716669T patent/ATE309268T1/de active
- 2002-01-21 SK SK1049-2003A patent/SK10492003A3/sk unknown
- 2002-01-21 NZ NZ551802A patent/NZ551802A/xx not_active IP Right Cessation
- 2002-01-21 EP EP10178465A patent/EP2322539A3/en not_active Withdrawn
- 2002-01-21 CA CA2792244A patent/CA2792244A1/en not_active Abandoned
- 2002-01-21 EP EP10178476A patent/EP2319861A1/en not_active Withdrawn
- 2002-01-21 NZ NZ527440A patent/NZ527440A/xx unknown
- 2002-01-21 WO PCT/EP2002/000546 patent/WO2002059148A2/en active Application Filing
2003
- 2003-07-25 NO NO20033364A patent/NO20033364L/no not_active Application Discontinuation
- 2003-07-25 ZA ZA200305764A patent/ZA200305764B/en unknown
- 2003-07-25 IS IS6895A patent/IS6895A/is unknown
2006
- 2006-12-21 US US11/614,716 patent/US7771728B2/en not_active Expired - Fee Related
2007
- 2007-10-17 IL IL186706A patent/IL186706A/en not_active IP Right Cessation
- 2007-11-16 AU AU2007234519A patent/AU2007234519B2/en not_active Ceased
2008
- 2008-06-11 JP JP2008152742A patent/JP5053933B2/ja not_active Expired - Fee Related
2010
- 2010-02-12 AU AU2010200549A patent/AU2010200549A1/en not_active Abandoned
- 2010-08-09 US US12/853,074 patent/US8323660B2/en not_active Expired - Fee Related
2011
- 2011-02-03 IL IL211037A patent/IL211037A/en not_active IP Right Cessation
- 2011-02-03 IL IL211038A patent/IL211038A0/en unknown
2012
- 2012-09-13 US US13/613,761 patent/US8715688B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2412722A1 (en)	2012-02-01
PL367125A1 (pl)	2005-02-21
NZ540764A (en)	2008-03-28
WO2002059148A9 (en)	2002-10-31
WO2002059148A2 (en)	2002-08-01
DE60207194D1 (de)	2005-12-15
NO20033364L (no)	2003-09-24
EP1616876A3 (en)	2006-04-12
BR0207067A (pt)	2004-06-15
CZ20032201A3 (en)	2004-03-17
IL186706A0 (en)	2008-02-09
AU2002247641B8 (en)	2008-03-13
CA2792244A1 (en)	2002-08-01
US8715688B2 (en)	2014-05-06
AU2010200549A1 (en)	2010-03-04
ATA1302001A (de)	2002-12-15
EP2322539A2 (en)	2011-05-18
EP2322539A3 (en)	2011-09-07
CA2436057C (en)	2012-12-18
KR20030082574A (ko)	2003-10-22
ES2252438T3 (es)	2006-05-16
WO2002059148A3 (en)	2003-07-31
MXPA03006702A (es)	2005-04-08
NZ565349A (en)	2009-07-31
PL209115B1 (pl)	2011-07-29
EP1630172A3 (en)	2006-05-03
JP5053933B2 (ja)	2012-10-24
EP1630172B1 (en)	2015-06-10
RU2003125967A (ru)	2005-03-10
JP2008291035A (ja)	2008-12-04
PL214482B1 (pl)	2013-08-30
DE60207194T2 (de)	2006-08-03
IL157082A0 (en)	2004-02-08
KR20080107477A (ko)	2008-12-10
IL211038A0 (en)	2011-04-28
KR100901915B1 (ko)	2009-06-10
CA2436057A1 (en)	2002-08-01
ATE309268T1 (de)	2005-11-15
US7968297B2 (en)	2011-06-28
RU2289817C2 (ru)	2006-12-20
US20130034575A1 (en)	2013-02-07
CN1649894A (zh)	2005-08-03
US20080038287A1 (en)	2008-02-14
US8323660B2 (en)	2012-12-04
EP1630172A2 (en)	2006-03-01
HUP0402048A2 (hu)	2005-01-28
IL211037A (en)	2013-07-31
NO20033364D0 (no)	2003-07-25
KR20090101973A (ko)	2009-09-29
NZ527440A (en)	2006-02-24
AU2007234519A1 (en)	2007-12-13
EP1355930B1 (en)	2005-11-09
WO2002059148A8 (en)	2003-01-16
EP2319861A1 (en)	2011-05-11
US20110020402A1 (en)	2011-01-27
IL211037A0 (en)	2011-04-28
IS6895A (is)	2003-07-25
DK1355930T3 (da)	2006-03-06
EP1355930A2 (en)	2003-10-29
EP1616876A2 (en)	2006-01-18
SK10492003A3 (sk)	2004-07-07
KR100851728B1 (ko)	2008-08-11
CN101492496A (zh)	2009-07-29
JP2004531476A (ja)	2004-10-14
AU2002247641B2 (en)	2007-08-23
US7771728B2 (en)	2010-08-10
AT410798B (de)	2003-07-25
HUP0402048A3 (en)	2010-01-28
ZA200305764B (en)	2004-07-26
AU2007234519B2 (en)	2009-11-12
US20050037444A1 (en)	2005-02-17
IL186706A (en)	2010-12-30
KR20080029016A (ko)	2008-04-02
NZ551802A (en)	2008-04-30

Publication	Publication Date	Title
PL392964A1 (pl)	2011-01-03	Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
WO2004009124A3 (en)	2004-04-08	Ghrelin-carrier conjugates
WO2002056905A3 (en)	2003-10-09	Molecular antigen array
IL166227A0 (en)	2006-01-15	Vaccine compositions containing amyloid beta1-6 antigen arrays
UA87093C2 (ru)	2009-06-25	ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
WO2003039225A3 (en)	2004-03-04	Antigen arrays comprising rankl for treatment of bone disease
WO2003011899A3 (en)	2004-02-26	Antigenic polypeptides
WO2000073430A3 (de)	2001-03-29	Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
WO2003059386A3 (en)	2004-03-11	Prion protein carrier-conjugates
MXPA04003900A (es)	2004-07-08	Disposiciones de antigenos para el tratamiento de enfermedades oseas.